🇺🇸 FDA

Intelligence · Clinical Pipeline

Oncology · Phase II

Oncology programs at Phase II — ClinicalTrials.gov pipeline intelligence.

Programs
2,640

Quick answer

Oncology Phase II programs: NovaPharmaNews indexes 2,640 matching clinical development programs from ClinicalTrials.gov with sponsor, modality, and NCT cross-links.

Top sponsors

Page 32 of 55

  1. MRTX1719

    Bristol-Myers Squibb Australia Pty Ltd

    Advanced or Metastatic Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  2. MRx0518

    4D Molecular Therapeutics

    Oncology

    phase 2 small molecule terminated

    1 trial

  3. MRx0518

    4D Molecular Therapeutics

    Urothelial Carcinoma

    phase 2 small molecule terminated

    1 trial

  4. MT-401

    Marker Therapeutics

    Acute Myeloid Leukemia

    phase 2 small molecule terminated

    1 trial

  5. MYCOPHENOLATE MOFETIL, Rilvegostomig, RAMUCIRUMAB, INFLIXIMAB

    AstraZeneca AB

    Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  6. MaaT013, Placebo de MaaT013 - Major ingredients: Calcium carbonate; Xanthan gum; Alimentary colorant; E150d: caramel color; HCl;Purified water

    Pari Pharma GmbH

    Melanoma

    phase 2 small molecule active

    1 trial

  7. MaaT033 capsule

    Regeneron UK Limited

    NSCLC (Advanced Non-small Cell Lung Cancer)

    phase 2 small molecule active

    1 trial

  8. Mekinist 2 mg film-coated tablets, Hydroxychloroquine sulfate Accord 200mg film-coated tablets, Mekinist 0.5 mg film-coated tablets

    Ningbo Cancer Hospital

    Metastatic refractory Pancreatic Cancer

    phase 2 small molecule active

    1 trial

  9. Mektovi 15 mg film-coated tablets, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Braftovi 75 mg hard capsules

    Ningbo Cancer Hospital

    BRAF(V600) mutation-positive melanoma with brain metastasis (MBM)

    phase 2 small molecule active

    1 trial

  10. Mektovi 15 mg film-coated tablets, Tyverb 250 mg film-coated tablets, Vinorelbine Accord 10 mg/ml concentraat voor oplossing voor infusie

    Disc Medicine

    metastatic colorectal cancer with a proven RAS mutation after failure of standard systemic treatment regimens including at least 5- FU/capecitabine-oxaliplatin and irinotecan based standard treatment (unless contra-indications for either oxaliplatin or irinotecan)

    phase 2 small molecule active

    1 trial

  11. Metformin Hydrochloride ER

    Atrium Therapeutics

    Sarcoma Metastatic

    phase 2 small molecule active

    1 trial

  12. Methotrexate

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Primary Central Nervous System Lymphoma

    phase 2 small molecule active

    1 trial

  13. Methotrexate tablets

    The First People's Hospital of Lianyungang

    Solid Tumors

    phase 2 small molecule active

    1 trial

  14. Midazolam-ratiopharm® 2 mg/ml orale Lösung, JNJ-42756493, JNJ-42756493, Metformin HEXAL 1000 mg Filmtabletten, JNJ-42756493

    Janssen-Cilag International N.V.

    Urothelial cancer

    phase 2 small molecule active

    1 trial

  15. Midostaurin

    Novartis Pharmaceuticals

    Acute Myeloid Leukemia

    phase 2 small molecule completed

    1 trial

  16. Mifamurtide

    Takeda

    Osteosarcoma

    phase 2 small molecule terminated

    1 trial

  17. Mifepristone

    CORCEPT THERAPEUTICS INC

    Non-Small Cell Lung Cancer (NSCLC)

    phase 2 small molecule terminated

    1 trial

  18. Mitomycin C

    HALOZYME THERAPEUTICS, INC.

    Bladder Cancer

    phase 2 small molecule completed

    1 trial

  19. Mitomycin C

    United Therapeutics Europe Ltd

    Bladder Cancer

    phase 2 small molecule active

    1 trial

  20. Mitoxantrone Hydrochloride Liposome

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Diffuse Large B-cell Lymphoma

    phase 2 small molecule active

    1 trial

  21. Mitoxantrone liposome

    The First People's Hospital of Lianyungang

    Relapsed or Refractory Acute Myeloid Leukemia

    phase 2 small molecule active

    1 trial

  22. MoLuoDan

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Gastric Precancerous Condition

    phase 2 small molecule active

    1 trial

  23. Modakafusp Alfa

    Teva Generics B.V

    Neoplasms

    phase 2 small molecule terminated

    1 trial

  24. Modakafusp Alfa

    Teva Pharma GmbH

    Neoplasms

    phase 2 small molecule terminated

    1 trial

  25. Monalizumab

    MedImmune

    Advanced Solid Tumors

    phase 2 small molecule active

    1 trial

  26. Mosunetuzumab

    Adaptive Biotechnologies Corp

    Diffuse Large B-Cell Lymphoma (DLBCL)

    phase 2 small molecule active

    1 trial

  27. Mosunetuzumab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Follicular Lymphoma

    phase 2 small molecule active

    1 trial

  28. Mosunetuzumab, Mosunetuzumab, Revlimid 5 mg hard capsules, Revlimid 10 mg hard capsules, Mosunetuzumab, Mosunetuzumab, Mosunetuzumab, RoActemra 20 mg/mL concentrate for solution for infusion

    Hoffmann-La Roche

    Follicular Lymphoma (FL)

    phase 2 small molecule active

    1 trial

  29. Mosunetuzumab, Mosunetuzumab, TOCILIZUMAB , BRUKINSA 80 mg hard capsules

    Fondazione Telethon ETS

    Follicular lymphoma

    phase 2 small molecule active

    1 trial

  30. Motixafortide

    Regeneron UK Limited

    Pancreatic Cancer

    phase 2 small molecule active

    1 trial

  31. Muc1/CLL1/CD33/CD38/CD56/CD123-specific gene-engineered T cells

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Acute Myeloid Leukemia

    phase 2 mab active

    1 trial

  32. Multi-epitope HER2 Peptide Vaccine TPIV100

    United Therapeutics Europe Ltd

    Breast Adenocarcinoma

    phase 2 mab active

    1 trial

  33. Myocet (Non-pegylated liposomal doxorubicin (NPLD))

    Sana Biotechnology

    Breast Cancer

    phase 2 small molecule completed

    1 trial

  34. NALIRIFOX+Adebrelimab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Pancreatic Ductal Adenocarcinoma (PDAC)

    phase 2 small molecule active

    1 trial

  35. NAP (Naptumomab estafenatox)

    BRIGHT MINDS BIOSCIENCES INC.

    Non-small Cell Lung Cancer

    phase 2 small molecule completed

    1 trial

  36. NDV01 intravesical controlled release formulation of gemcitabine and docetaxel

    RELMADA THERAPEUTICS, INC.

    Non Muscle Invasive Bladder Cancer

    phase 2 small molecule active

    1 trial

  37. NEO-201 in combination with pembrolizumab

    Chongqing Precision Biotech Co., Ltd

    Non Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  38. NERATINIB

    PUMA BIOTECHNOLOGY, INC.

    Stage IV (Metastatic) Breast Cancer

    phase 2 small molecule terminated

    1 trial

  39. NERATINIB, Sindiar 2 mg cápsulas duras

    Ningbo Cancer Hospital

    HER2 positive (HER2+), Hormone Receptor positive (HR+) Early-stage Breast Cancer.

    phase 2 small molecule active

    1 trial

  40. NEXPOVIO 20 mg film-coated tablets, HOLOXAN 1 g polvere per soluzione per infusione, Decadron “8 mg/2 ml Soluzione iniettabile”, ETOPOSIDE TEVA 20 mg/ml, concentrato per soluzione per infusione.

    Fondazione Telethon ETS

    Relapsed or Refractory Peripheral T-cell Lymphomas

    phase 2 small molecule active

    1 trial

  41. NIVOLUMAB, TEDOPI

    Fondazione Telethon ETS

    metastatic non-small-cell lung cancer

    phase 2 small molecule active

    1 trial

  42. NK cell and PD-1 antibody

    The First People's Hospital of Lianyungang

    Non-small Cell Lung Cancer

    phase 2 other completed

    1 trial

  43. NK cells

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Hepatocellular Carcinoma

    phase 2 mab active

    1 trial

  44. NK cells

    Hospital Authority, Hong Kong

    Hepatocellular Carcinoma

    phase 2 mab active

    1 trial

  45. NKTR-102

    Nektar Therapeutics UK Limited

    Colorectal Cancer

    phase 2 small molecule completed

    1 trial

  46. NKTR-102

    Nektar Therapeutics UK Limited

    Tumor

    phase 2 small molecule completed

    1 trial

  47. NKTR-102 100 mg/m2

    Nektar Therapeutics UK Limited

    Tumor

    phase 2 small molecule completed

    1 trial

  48. NKTR-102 145 mg/m2

    Nektar Therapeutics UK Limited

    Malignant Solid Tumor

    phase 2 small molecule completed

    1 trial

Frequently asked questions

How many oncology Phase II programs exist?

2,640 programs match both the therapeutic area and stage filters in our published index.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.